Expertise. Innovation. Reliability.With over 15 years of experience in oligonucleotide development and production, and over 1000 sequences manufactured, Avecia has played an integral role in the advancing oligo therapeutic market. Our mission is to continue to build value for our customers, as they progress through drug development into commercialization. And as a new member of the Nitto Corporation (www.nitto.com), Avecia is committed to the future of the oligonucleotide market. We are driven by innovative ideas and flexible solutions, designed to provide our customers with the best in service, quality, and technology.
Our FDA inspected Contract Manufacturing Organization (CMO) in Milford, MA is aligned to the needs of the pre-clinical, clinical, and launched product oligonucleotide markets. Our aim is to leverage our wealth of experience, and our understanding of the regulatory needs in each of these segments, to ensure we exceed our customer’s expectations.
Our new Cincinnati, OH location provides distinct advantages to our customers, including additional security of supply; Avecia is pleased to offer our customers cGMP large scale oligo manufacturing capacity in two separate facilities. Our Cincinnati facility also provides additional pre-clinical oligo manufacturing services, along with cGMP small molecule production.
Our portfolio of services includes process and analytical development, pre-clinical and cGMP oligo manufacture, and quality control testing, including on site ICH stability storage and testing. All of our customers benefit from our experienced supply chain team, as well a quality team ready to manage the regulatory needs of projects at all phases of development.
From pre-clinical stages to commercial launch, you can count on Avecia.